Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
NEW YORK - Johnson & Johnson on Tuesday reported disappointing third-quarter sales on Tuesday, but beat earnings forecasts thanks to cost-cutting and raised its full-year profit forecast.
1 of 1 
| JNJ | 62.95 |  0.58 |
The diversified healthcare company said net earnings rose 1.1 percent to $3.35 billion, or $1.20 per share. That compared with $3.31 billion, or $1.17 per share, in the year-earlier period. Analysts polled by Thomson Reuters I/B/E/S had forecast $1.13 per share.
Company sales fell 5.3 percent to $15.08 billion, shy of the analysts' forecast of $15.22 billion.
The company said prescription drug sales fell more than 14 percent, hurt by generic competition for its Topamax epilepsy drug and Risperdal schizophrenia treatment.
J&J shares fell 1.6 percent to $61.55 in premarket trading.
A Chinese-born engineer was sentenced Monday to more than 15 years in prison for...
China has closed what it claims to be the largest hacker training website in the...
Partners 
|
© 2010 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
